Literature DB >> 24559774

Nurse scientists in cancer cooperative groups.

Deborah Watkins Bruner, Ann O'Mara.   

Abstract

OBJECTIVES: To review the significant advances in cancer prevention, detection, treatment, and symptom management among the National Cancer Institute (NCI)-supported clinical trials cooperative groups, the Institute of Medicine (IOM) recommendations for restructuring of the national clinical trials infrastructure, and to discuss the contributions nurses have made in national clinical trials. DATA SOURCE: Published cooperative group manuscripts and NCI data.
CONCLUSION: The NCI-sponsored clinical trials cooperative groups have conducted major evidence-based, practice-changing clinical trials. Despite the advances, challenges in the process of clinical trials have caused the NCI to restructure the clinical trials network to improve efficiencies and decrease time from concept to protocol development to clinical trials completion. IMPLICATIONS FOR NURSING PRACTICE: Nurse investigators work with the cooperative groups for a number of reasons, including access to a large multisite population of cancer patients, making findings more generalizable. There are also increasing opportunities for areas of research including biomechanistic understanding of symptoms and symptom therapies, survivorship, and cancer care delivery.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer clinical trials; NCI cooperative groups; symptom management

Mesh:

Year:  2013        PMID: 24559774     DOI: 10.1016/j.soncn.2013.12.002

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  2 in total

1.  Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions.

Authors:  Stephanie Gilbertson-White; Nicole Bohr; Karen E Wickersham
Journal:  Biol Res Nurs       Date:  2017-05-16       Impact factor: 2.522

2.  Activities supporting the growth of Clinical Trial Networks in Australia.

Authors:  Fiona Nemeh; Rachelle Buchbinder; Carmel M Hawley; Mark R Nelson; Jacqui G Waterkeyn; Christopher M Reid
Journal:  Trials       Date:  2022-01-28       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.